| Literature DB >> 29417085 |
Vida Eraghi1, Abdollah Derakhshandeh1, Arsalan Hosseini1, Azar Motamedi-Boroojeni1.
Abstract
Mycobacterium avium subsp. paratuberculosis (MAP) is the etiologic agent of Johne's disease in ruminants and there has been a shift in the public health approach to MAP and human diseases like Crohn's disease. The prevention of infection by MAP in ruminants is thought to deter the high impact of economic losses in the level of dairy industry and possible spreading of this pathogen in dairy products. The present study was done to investigate the construction and expression of the soluble form of a novel fusion protein, consisting of Heparin-binding hemagglutinin (HBHA) and high antigenic region of Fibronectin Attachment Protein-P (FAP-P), in order to introduce as a Th1 inducer subunit vaccine against MAP. HBHA is a mycobacterial adhesin and it has been demonstrated that a HBHA-specific IFN-γ response, in latent M. tuberculosis infection, depends on the methylation of the antigen. Further, FAP-P induces Th1 polarization. Because methylation of HBHA was not performed in E. coli, Pichia pastoris was chosen as the host. The desired fusion protein had a similar 3D structure to that of HBHA with its native form and post-translational methylation in C-terminal. Hence, the uptake of the purified fusion protein will be done by M cells because of HBHA, and cell-mediated immunity will be induced because of both antigens. Eventually, successful construction and expression of the newly-designed chimeric protein under the mentioned conditions is reported in this article.Entities:
Keywords: FAP-P; HBHA; Mycobacterium avium subsp; fusion protein; in silico
Year: 2017 PMID: 29417085 PMCID: PMC5762988 DOI: 10.22099/mbrc.2017.26522.1286
Source DB: PubMed Journal: Mol Biol Res Commun ISSN: 2322-181X
Figure 13D structure alignment of chimeric protein with native form of HBHA. Alignment of HBHA-FAP (in red) with native HBHA (in blue).
Figure 2Western blot analysis of recombinant protein . Lane M: protein ladder (Cinnagen PR911654 [SL7012 ]), Lane 1: negative control, Lane 2: recombinant HBHA-FAP protein 120 hr of post-induction with 0.5% methanol concentration with the same expected size.